Firebrick Pharma (ASX:FRE) Broadens Nasodine Range Ahead of US Pharmacy Push

Aditi Sarkar

23 October 2026 10:16 PM AEDT

Firebrick Pharma (ASX:FRE) Broadens Nasodine Range Ahead of US Pharmacy Push

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Decision announced to actively enter the US retail pharmacy market with Nasodine products.
Non-executive director Al Moghaddam appointed US Commercial Director.
Nasodine Sinus Rinse launched on 21 October 2026.
Cash operating expenses fell to $729k, supported by a $293k R&D tax incentive receipt.

Consumer healthcare developer Firebrick Pharma Limited (ASX:FRE) shifted attention toward a wider US pharmacy presence for its Nasodine products in the September 2026 quarter. The retail initiative followed growth in online activity, while a new product launch expanded the range beyond its established nasal spray.

The US Retail Strategy

On 29 September 2026, Firebrick announced its decision to actively enter the US retail pharmacy market with Nasodine products. The move followed growth in online sales and the company’s attendance in August at the National Association of Chain Drug Stores retail trade expo in Boston, after which management developed a plan to accelerate US sales.

Al Moghaddam, Firebrick’s US-based non-executive director, has taken on the role of US Commercial Director to lead retail marketing. The business indicated he has experience managing distribution through major US pharmacy chains and pharmaceutical wholesale networks.

A Wider Nasodine Line-Up

Firebrick continued work on the next products in its Nasodine range and announced the launch of the Nasodine Sinus Rinse on 21 October 2026. That comes after the addition of Nasodine Throat Spray earlier in 2026, giving the company a broader range of upper respiratory tract care products.

In July, the company also provided an investor update linked to its CEO’s participation in investor conferences in Melbourne and Sydney.

Costs, Receipts and Cash

Cash operating expenses for the quarter were $729k, down $110k from the June quarter, mainly due to research and development spending being $98k lower. Separately, the business received a $293k R&D Tax Incentive payment related to R&D costs incurred in FY26.

Sales receipts were down $39k on the June quarter, which the company attributed to seasonal factors, while noting continued growth on an annualised basis, especially in the US. Firebrick held cash of $875k at 30 September 2026, with net operating cash outflows of $398k for the quarter. Payments to related parties totalled $285k.

Commercial Priorities Ahead

FAQs

Q: What is Firebrick Pharma’s main product?

A: Nasodine Nasal Spray, a povidone-iodine based consumer health product.

Q: What did Firebrick announce approximately the US?

A: It will actively enter the US retail pharmacy market with Nasodine products.

Q: Who is leading the US retail push?

A: Non-executive director Al Moghaddam, as US Commercial Director.

Q: What new product was launched?

A: Nasodine Sinus Rinse, launched on 21 October 2026.

Q: How much cash did Firebrick hold at quarter end?

A: $875k at 30 September 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.